RIVFLOZA®

Hold Company

NOVO

Learn More

Dosage and Administration

SOLUTION;INJECTION

Specification

EQ 80MG BASE/0.5ML (EQ 160MG BASE/ML); EQ 128MG BASE/0.8ML (EQ 160MG BASE/ML); EQ 160MG BASE/ML (EQ 160MG BASE/ML)

Indication

Rivfloza® is indicated to lower urinary oxalate levels in children 9 years of age and older and adults with primary hyperoxaluria type 1 (PH1) and relatively preserved kidney function.

Use

Instructions for Use

API

NEDOSIRAN SODIUM

API Structure

We Supply

NEDOSIRAN

Drug Patent

Patent No	Expiration Date
10351854	2035/10/9
10738311	2035/10/9
11053502	2035/10/29
11286488	2038/10/12
11359203	2035/10/9
11661604	2038/10/12

API Patent

Patent No	Expiration Date
10351854	2035/10/9
10738311	2035/10/9
11053502	2035/10/29
11286488	2038/10/12
11359203	2035/10/9
11661604	2038/10/12

Note: The patent information provided herein is derived solely from publicly available data in the FDA Orange Book (or other cited sources) and is presented for general informational purposes only. Actual patent status may vary based on jurisdictional rulings, regulatory extensions or other factors.